LH · Company research
Labcorp Holdings Inc. (LH): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
29records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Labcorp Holdings Inc. $LH Shares Sold by Birch Hill Investment Advisors LLC - MarketBeat | Labcorp Holdings Inc. $LH Shares Sold by Birch Hill Investment Advisors LLC MarketBeat | View source ↗ | MarketBeat | Oct 18, 2026 | neutral | 0 | 0.6 |
| Labcorp Holdings Inc. $LH Shares Sold by Curated Wealth Partners LLC - MarketBeat | Labcorp Holdings Inc. $LH Shares Sold by Curated Wealth Partners LLC MarketBeat | View source ↗ | MarketBeat | Oct 17, 2026 | neutral | 0 | 0.6 |
| OPKO Health to Sell Select BioReference Assets to Labcorp for $722M | OPKO Health announced an agreement to sell select BioReference assets to Labcorp for $722 million in cash plus up to $150 million in earnouts. The deal includes the 4Kscore Test, specialty testing operations, and over 80 patient service centers. OPKO aims to focus on its biopharmaceutical business, while Labcorp expects $250 million in first-year revenue from the acquisition. OPK stock rose 17.5% following the announcement. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| PACS Group, Inc. (PACS) Surges 6.2%: Is This an Indication of Further Gains? | PACS Group shares jumped 6.2% to $47.75 on investor optimism ahead of Q3 2026 earnings release. The company is expected to report 75% earnings growth and 8.1% revenue growth. However, with unchanged consensus EPS estimates over the past 30 days, analysts caution that the stock may lack momentum for sustained gains without positive estimate revisions. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | neutral | 0 | 1 |
| PACS Group, Inc. (PACS) Surges 6.2%: Is This an Indication of Further Gains? | PACS Group shares jumped 6.2% to $47.75 on investor optimism ahead of Q3 2026 earnings release. The company is expected to report 75% earnings growth and 8.1% revenue growth. However, with unchanged consensus EPS estimates over the past 30 days, analysts caution that the stock may lack momentum for sustained gains without positive estimate revisions. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | neutral | 0 | 1 |
| Labcorp (LH) Stock Looks In Step With Its Cash Flow Outlook - Yahoo Finance | Labcorp (LH) Stock Looks In Step With Its Cash Flow Outlook Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| Why Is Opko Health Stock Gaining Thursday? - OPKO Health (NASDAQ:OPK), Labcorp Holdings (NYSE:LH) - Benzinga | Why Is Opko Health Stock Gaining Thursday? - OPKO Health (NASDAQ:OPK), Labcorp Holdings (NYSE:LH) Benzinga | View source ↗ | Benzinga | Oct 15, 2026 | neutral | 0 | 0.6 |
| Three stocks poised to beat estimates this earnings season - TradingView | Three stocks poised to beat estimates this earnings season TradingView | View source ↗ | TradingView | Oct 15, 2026 | neutral | 0 | 0.6 |
| Labcorp to buy select assets of OPKO’s BioReference Health for up to $872M - Seeking Alpha | Labcorp to buy select assets of OPKO’s BioReference Health for up to $872M Seeking Alpha | View source ↗ | Seeking Alpha | Oct 15, 2026 | neutral | 0 | 0.6 |
| A prostate cancer blood test may reach more patients if Labcorp completes its deal - Stock Titan | A prostate cancer blood test may reach more patients if Labcorp completes its deal Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Q2 Earnings Outperformers: Labcorp (NYSE:LH) And The Rest Of The Testing & Diagnostics Services Stocks - StockStory | Q2 Earnings Outperformers: Labcorp (NYSE:LH) And The Rest Of The Testing & Diagnostics Services Stocks StockStory | View source ↗ | StockStory | Oct 14, 2026 | neutral | 0 | 0.6 |
| Arianna Huffington's Thrive Global and Labcorp pair five health measures with habit advice - Stock Titan | Arianna Huffington's Thrive Global and Labcorp pair five health measures with habit advice Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Labcorp (LH): Is Its Earnings Discount Worth the Growing Investment Bill? - Yahoo Finance | Labcorp (LH): Is Its Earnings Discount Worth the Growing Investment Bill? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| LH Oct 2026 310.000 call (LH261016C00310000) Interactive Stock Chart - Yahoo! Finance Canada | LH Oct 2026 310.000 call (LH261016C00310000) Interactive Stock Chart Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 11, 2026 | neutral | 0 | 0.6 |
| LH Jan 2027 360.000 call (LH270115C00360000) Stock Historical Prices & Data - Yahoo! Finance Canada | LH Jan 2027 360.000 call (LH270115C00360000) Stock Historical Prices & Data Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 10, 2026 | neutral | 0 | 0.6 |
| Precision Trading with Laboratory Corporation Of America Holdings (LH) Risk Zones - Stock Traders Daily | Precision Trading with Laboratory Corporation Of America Holdings (LH) Risk Zones Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 9, 2026 | neutral | 0 | 0.6 |
| Global Decentralized Clinical Trials Market Size, Trends, and Forecast, 2025-2030 | AI, Wearables, and Cloud-Based Platforms Fuel 13.7% CAGR to $18.8 Billion | The global Decentralized Clinical Trials (DCT) market is valued at $8.8 billion in 2025 and is projected to reach $18.8 billion by 2030, growing at a 13.7% CAGR. Growth is driven by AI integration, wearable technologies, cloud-based platforms, and increased adoption of remote research capabilities across pharmaceutical, biotechnology, and contract research sectors. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| Global Decentralized Clinical Trials Market Size, Trends, and Forecast, 2025-2030 | AI, Wearables, and Cloud-Based Platforms Fuel 13.7% CAGR to $18.8 Billion | The global Decentralized Clinical Trials (DCT) market is valued at $8.8 billion in 2025 and is projected to reach $18.8 billion by 2030, growing at a 13.7% CAGR. Growth is driven by AI integration, wearable technologies, cloud-based platforms, and increased adoption of remote research capabilities across pharmaceutical, biotechnology, and contract research sectors. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| Top Labcorp (LH) Competitors 2026 - MarketBeat | Top Labcorp (LH) Competitors 2026 MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| Labcorp (NYSE:LH) Stock Price Breaks Above Two Hundred Day Moving Average - Should You Sell? - MarketBeat | Labcorp (NYSE:LH) Stock Price Breaks Above Two Hundred Day Moving Average - Should You Sell? MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| LH Mar 2027 320.000 call (LH270319C00320000) Stock Price, News, Quote & History - Yahoo! Finance Canada | LH Mar 2027 320.000 call (LH270319C00320000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| LH Jan 2027 360.000 call (LH270115C00360000) Stock Price, News, Quote & History - Yahoo! Finance Canada | LH Jan 2027 360.000 call (LH270115C00360000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 8, 2026 | neutral | 0 | 0.6 |
| LH Oct 2026 310.000 call (LH261016C00310000) Stock Price, News, Quote & History - Yahoo! Finance Canada | LH Oct 2026 310.000 call (LH261016C00310000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 7, 2026 | neutral | 0 | 0.6 |
| Here's Why Labcorp Holdings (LH) is a Strong Value Stock | Labcorp Holdings (LH), a leading healthcare diagnostics company, receives a #3 (Hold) rating on the Zacks Rank with a VGM Score of B. The company shows attractive valuation metrics with a forward P/E ratio of 16.84 and has seen three analyst upward earnings revisions in the last 60 days, with the consensus estimate increasing to $18.32 per share for fiscal 2026. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | neutral | 0 | 1 |
| Here's Why Labcorp Holdings (LH) is a Strong Value Stock | Labcorp Holdings (LH), a leading healthcare diagnostics company, receives a #3 (Hold) rating on the Zacks Rank with a VGM Score of B. The company shows attractive valuation metrics with a forward P/E ratio of 16.84 and has seen three analyst upward earnings revisions in the last 60 days, with the consensus estimate increasing to $18.32 per share for fiscal 2026. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | neutral | 0 | 1 |
| Labcorp (LH) Stock Forecast and Price Target 2026 $LH - MarketBeat | Labcorp (LH) Stock Forecast and Price Target 2026 $LH MarketBeat | View source ↗ | MarketBeat | Oct 6, 2026 | neutral | 0 | 0.6 |
| 3 Reasons LH is Risky and 1 Stock to Buy Instead - Yahoo Finance | 3 Reasons LH is Risky and 1 Stock to Buy Instead Yahoo Finance | View source ↗ | Yahoo Finance | Aug 25, 2026 | neutral | 0 | 0.6 |
| Why Labcorp Holdings (LH) Stock Is Up Today - Quiver Quantitative | Why Labcorp Holdings (LH) Stock Is Up Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 23, 2026 | neutral | 0 | 0.6 |
| 3 Reasons LH is Risky and 1 Stock to Buy Instead - Yahoo Finance | 3 Reasons LH is Risky and 1 Stock to Buy Instead Yahoo Finance | View source ↗ | Yahoo Finance | Jun 25, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.